Dr. Abdallah SHBAIR

## Doctor Information - 2006-2012 – Uludağ University Faculty of Medicine / Bursa (Undergraduate) - 2013-2017 – Marmara University Faculty of Medicine, Department of Internal Medicine / Istanbul (Internal Medicine Residency) - 2018-2021 – Bezmialem Foundation University Faculty of Medicine, Division of Medical Oncology / Istanbul (Medical Oncology Fellowship) ## Areas of Expertise - Breast Cancer - Lung Cancer - Urogenital Cancers (Kidney, Bladder, Testis) - Gastrointestinal System Cancers (Esophagus, Stomach, Colon, Pancreas) - Gynecological Cancers (Uterus, Cervix, Ovary) - Skin Cancer (Malignant Melanoma) ## Professional Experiences - 2017-2018 : Private Istanbul Medipol Hospital (Internal Medicine Specialist) - 2021 – Present : Emsey Hospital (Medical Oncology Specialist) ## Publications #### Internal Medicine Specialty Thesis · Possible effects of sphingosine-1 phosphate receptor agonists in the prevention of experimental contrast nephropathy in rats. Specialty Thesis in Medicine, Marmara University Faculty of Medicine, Department of Internal Medicine, 2017. #### Articles Published in International Peer-Reviewed Journals (SCI/SCI-E) (Original English titles preserved as published) (Burayı seninle daha önce çevirmiştik, 1–11 arası makaleler zaten İngilizce olduğu için aynen bırakıldı.) ### Papers Presented at International Scientific Meetings and Published in Abstract Books (Posters) 1. Abdallah Shbair, Seda Kutlug Agackiran, Zarife Ozdemir, Ozlem Tugce Cilingir Kaya, Naziye Ozkan, Sule Cetinel, Berrak Yegen, Mehmet Koc. “Sphingosine-1 receptor agonist SEW2871 ameliorates contrast-induced nephropathy in rats.” American Society of Nephrology, USA, 2017. 2. Seda Kutlug Agackiran, Abdallah Shbair, Zarife Ozdemir, Ozlem Tugce Cilingir Kaya, Naziye Ozkan, Sule Cetinel, Berrak Yegen, Mehmet Koc. “Ala-apelin, an apelin receptor antagonist, ameliorates contrast-induced nephropathy in rats.” American Society of Nephrology, USA, 2017. ### Papers Presented at National Scientific Meetings and Published in Abstract Books 1. Abdallah TM Shbair, Mesut Şeker, Tarık Demir, Altay Aliyev, Mehmet Beşiroğlu, Hacı M. Türk. A rare entity: teratoma growing syndrome. 23rd National Cancer Congress, April 2019. 2. Tarık Demir, Murat Araz, Murat Sarı, Ibrahim Çil, Abdallah T M Shbair, Altay Aliyev, Ezgi Çoban, Mehmet Beşiroğlu, Mesut Şeker, Hacı M. Türk. First-line treatment of diabetic metastatic castration-resistant prostate cancer patients: PRODmer study. 23rd National Cancer Congress, April 2019. 3. Ezgi Çoban, Mehmet Beşiroğlu, Tarık Demir, Altay Aliyev, Abdallah Shbair, Mesut Şeker, Hacı Mehmet Türk. Clinicopathological factors associated with pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy. 23rd National Cancer Congress, April 2019. 4. Abdallah TM Shbair. Clinicopathological factors affecting the pathological response level of neoadjuvant anti-HER2 treatments in locally advanced HER2-positive breast cancer patients. Current Developments in Cancer 2021; Innovations in Breast Cancer e-Symposium. 5. Abdallah TM Shbair. Effect of neutrophil/lymphocyte ratio on survival in metastatic non-small cell lung cancer. National Lung Health Congress (UASK 2021), October 2021. 6. Ayşe Betül Oktay, Haci Mehmet Türk, Abdusselim Adil Peker, Dilek Hacer Çeşme, Alpay Alkan, Alpaslan Mayadağli, Mesut Şeker, Ayşe İrem Yasin, Ahmet Kaya, Temel Fatih Yilmaz, Abdallah Shbair, Mehmet Ali Gültekin. Differentiation of Brain Metastases From Brain MRI With Deep CNN. 30th International Congress on Diagnostic and Interventional Neuroradiology and Head-Neck Radiology, Istanbul, Turkey, February 17–21, 2021. ### International Scientific Research Projects (Phase III) Participated as Co-Investigator 1. A phase 3 multicenter, randomized, double-blind, active-controlled clinical trial evaluating the safety and efficacy of pembrolizumab (MK-3475) plus lenvatinib (E7080/MK-7902) versus lenvatinib monotherapy as first-line treatment in subjects with advanced hepatocellular carcinoma (LEAP-002). 2. A randomized phase 3, two-part study of cemiplimab (anti-PD1 antibody) in combination with platinum-based chemotherapy as first-line treatment in patients with advanced or metastatic non-small cell lung cancer. 3. A phase 3, randomized, double-blind, placebo-controlled, multicenter study (DUO-O) evaluating durvalumab, bevacizumab, and olaparib as maintenance therapy following durvalumab, chemotherapy, and bevacizumab combination in newly diagnosed advanced ovarian cancer patients. 4. A global phase 3, multicenter, randomized, double-blind efficacy study comparing zolbetuximab (IMAB362) plus CAPOX versus placebo plus CAPOX as first-line therapy in subjects with claudin (CLDN) 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. 5. A phase 3 study comparing erdafitinib versus vinflunine or docetaxel or pembrolizumab in patients with advanced urothelial cancer with selected FGFR gene alterations. 6. A phase 3 trial evaluating maintenance therapy with pembrolizumab plus pemetrexed versus pembrolizumab plus olaparib following induction with pembrolizumab plus platinum (carboplatin or cisplatin) and pemetrexed in subjects with metastatic non-squamous non-small cell lung cancer. ### Book Chapter Authorship 1. Abdallah TM SHBAIR. Supportive Treatments and Symptom Management in Oncology, Approach to Cancer-Associated Thromboembolism. Akademisyen Publishing. ISBN: 978-625-7401-53-1, DOI: 10.37609/akya.180.